SAN DIEGO, Sept. 29, 2025 — Oncolytics Biotech® Inc. (NASDAQ: ONCY) today announced a key update on its plan for a potential registration-directed clinical trial in first-line pancreatic ductal adenocarcinoma (PDAC). The company will meet with the U.S. Food and Drug Administration (FDA) in November 2025 to finalize the design of a pivotal Phase 3 study evaluating its proprietary oncolytic virus immunotherapy, pelareorep, in combination with standard chemotherapy and checkpoint inhibition. The proposed three-arm randomized trial will compare gemcitabine + nab-paclitaxel (GnP) alone, GnP plus pelareorep, and GnP plus pelareorep combined with a checkpoint inhibitor, with overall survival (OS) as the primary endpoint and a pre-specified interim efficacy analysis.
Science Significance
Pancreatic cancer remains one of the most lethal solid tumors, with a five-year survival rate below 12% and limited therapeutic options. Pelareorep is an intravenously delivered, proprietary oncolytic double-stranded RNA virus designed to selectively infect and replicate in tumor cells while activating both innate and adaptive immune responses. Previous studies have demonstrated its ability to convert immunologically “cold” tumors into “hot,” potentially enhancing responses to checkpoint inhibitors and chemotherapy.
The proposed trial represents a critical scientific advance by testing a triple-combination strategy in the first-line setting, where most patients receive only chemotherapy. Incorporating an interim analysis will enable early detection of meaningful clinical signals and could accelerate the path to approval if survival benefits are confirmed. This scientifically rigorous design leverages post-hoc pooled data suggesting that pelareorep plus chemotherapy achieved a two-year survival rate of approximately 22% compared to historical rates of around 9%, underscoring the potential of this novel approach.
Regulatory Significance
Oncolytics’ plan to meet the FDA reflects a proactive regulatory strategy to secure alignment on trial design, statistical powering, and endpoint selection. By proposing overall survival as the primary endpoint—the gold standard for oncology approvals—the company demonstrates confidence in pelareorep’s ability to deliver a clinically meaningful benefit. The inclusion of a checkpoint inhibitor arm also anticipates the evolving regulatory landscape, which increasingly supports immunotherapy combinations in hard-to-treat malignancies. A positive outcome from this trial could position pelareorep for a Biologics License Application (BLA) submission and set a precedent for novel oncolytic virus therapies in pancreatic cancer.
Advertisement
Business Significance
For Oncolytics, success in this trial could transform the company from a development-stage biotech into a commercial-stage oncology leader. Pancreatic cancer is projected to become the second-leading cause of cancer-related death in the United States by 2030, representing a multi-billion-dollar market opportunity with limited competition in the first-line setting. Achieving FDA alignment and initiating a registration-directed trial could significantly strengthen Oncolytics’ strategic position for potential partnerships, licensing deals, or future acquisitions. The ability to demonstrate a survival benefit in this population would not only validate pelareorep’s platform but also enhance shareholder value and support expansion into other tumor types.
Patients’ Significance
For patients and their families, the implications of this trial are profound. Current first-line treatment—gemcitabine plus nab-paclitaxel—offers a median overall survival of less than one year, leaving an urgent need for more effective therapies. Pelareorep’s mechanism of activating anti-tumor immunity while synergizing with chemotherapy and checkpoint inhibitors offers the possibility of longer survival, deeper responses, and improved quality of life. The incorporation of an interim efficacy analysis means that patients could benefit sooner if early results show a clear survival advantage, accelerating potential access to this novel therapy.
Policy Significance
Oncolytics’ proposed study also aligns with broader healthcare policy priorities, including the Cancer Moonshot initiative and global efforts to improve outcomes in cancers with high unmet need. By embracing a three-arm design with combination immunotherapy, the trial reflects the FDA’s encouragement of innovative and adaptive clinical trial frameworks. Success could influence future policy decisions on trial endpoints, reimbursement models, and coverage guidelines for combination immunotherapy in pancreatic cancer, potentially setting a precedent for other emerging oncolytic virus therapies.
Transaction Highlights
Oncolytics Biotech plans to advance a pivotal, randomized Phase 3 registration-directed trial in first-line pancreatic cancer that will evaluate three treatment arms: gemcitabine plus nab-paclitaxel (GnP) as the control, GnP combined with the company’s proprietary oncolytic virus pelareorep, and GnP combined with pelareorep plus a checkpoint inhibitor. The proposed study will use overall survival (OS) as the primary endpoint, supported by a pre-specified interim efficacy analysis to allow early assessment of clinical benefit. The trial design is informed by post-hoc pooled clinical data showing that patients treated with pelareorep plus chemotherapy achieved a two-year survival rate of approximately 22%, compared to historical survival rates of about 9% for standard therapy alone. Oncolytics expects to meet with the U.S. Food and Drug Administration (FDA) in November 2025 to finalize the protocol and align on regulatory requirements. This trial is intended to position pelareorep as a first-in-class oncolytic immunotherapy for frontline pancreatic cancer, with the potential to create a significant commercial opportunity and establish a new treatment paradigm in this high-mortality disease.
Source: Oncolytics Biotech® Inc. Press Release
